(KPTI) Karyopharm Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US48576U1060
KPTI: Cancer, Drugs, Pharmaceuticals, Oncology, Medications
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of Selective Inhibitor of Nuclear Export (SINE) compounds. These compounds target the nuclear export protein exportin 1 (XPO1), a key regulator of cellular transport. The companys lead product, XPOVIO (selinexor), is approved for the treatment of relapsed or refractory multiple myeloma (RRMM) and relapsed or refractory diffuse large B-cell lymphoma (DLBCL). XPOVIO is also being investigated in combination with other therapies for various hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, and myelofibrosis.
Karyopharms pipeline includes additional SINE compounds such as eltanexor, verdinexor, and KPT-9274, which are in various stages of development for oncology and non-oncology indications. The company has established strategic partnerships to expand its global reach, including a license agreement with Menarini Group for selinexor in oncology and a collaboration with Antengene Therapeutics Limited for multiple compounds. Additionally, Karyopharm has a collaboration with Bristol Myers Squibb to evaluate the combination of mezigdomide and selinexor in relapsed/refractory multiple myeloma.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a robust R&D platform focused on cereblon E3 ligase modulators. The companys stock is listed on the NASDAQ under the ticker symbol KPTI and is classified under the Biotechnology sub-industry.
3-Month Forecast: Based on
Additional Sources for KPTI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
KPTI Stock Overview
| Market Cap in USD | 61m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2013-11-06 |
KPTI Stock Ratings
| Growth Rating | -92.6 |
| Fundamental | -25.9 |
| Dividend Rating | 0.0 |
| Rel. Strength | -56.5 |
| Analysts | 4.14/5 |
| Fair Price Momentum | 2.46 USD |
| Fair Price DCF | - |
KPTI Dividends
No Dividends PaidKPTI Growth Ratios
| Growth Correlation 3m | -60.1% |
| Growth Correlation 12m | -89.5% |
| Growth Correlation 5y | -97.3% |
| CAGR 5y | -54.45% |
| CAGR/Max DD 5y | -0.55 |
| Sharpe Ratio 12m | -2.56 |
| Alpha | -73.54 |
| Beta | 1.197 |
| Volatility | 106.30% |
| Current Volume | 62.6k |
| Average Volume 20d | 87.3k |
As of May 10, 2025, the stock is trading at USD 6.01 with a total of 62,645 shares traded.
Over the past week, the price has changed by -18.34%, over one month by +42.08%, over three months by -35.68% and over the past year by -62.55%.
Probably not. Based on ValueRay Fundamental Analyses, Karyopharm Therapeutics (NASDAQ:KPTI) is currently (May 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -25.88 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KPTI as of May 2025 is 2.46. This means that KPTI is currently overvalued and has a potential downside of -59.07%.
Karyopharm Therapeutics has received a consensus analysts rating of 4.14. Therefor, it is recommend to buy KPTI.
- Strong Buy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, KPTI Karyopharm Therapeutics will be worth about 2.8 in May 2026. The stock is currently trading at 6.01. This means that the stock has a potential downside of -53.41%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 48.6 | 709.3% |
| Analysts Target Price | 48.6 | 709.3% |
| ValueRay Target Price | 2.8 | -53.4% |